Rituximab
Treatment for Lupus
Typical Dosage: 1000 mg IV on days 1 and 15, repeated every 6-12 months
Effectiveness
70%
Safety Score
45%
Clinical Trials
36
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
1000 mg IV on days 1 and 15, repeated every 6-12 months
Time to Effect
3-6 months
Treatment Duration
Cycles (e.g., 2 infusions every 6-12 months), potentially lifetime
Evidence Quality
MODERATENumber Needed to Harm (NNH)
30(Treat 30 patients to see 1 additional serious adverse event)
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$800
Side Effect Mgmt:$700
Total Annual:$16,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$100,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$33,000
Cost per Remission
$66,000
Rituximab Outcomes
for Lupus
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+50%
Remission Rate
+25%
Common Side Effects
Infusion reactions
+15%
Infections
+20%
Progressive multifocal leukoencephalopathy (PML - very rare)
+0.01%
Sources:
Active Clinical Trials
3 active trials recruiting for Rituximab in Lupus
Anti-CD20 Antibodies for Treatment of SLE-PAH
NCT05828147RECRUITINGPHASE4
50 participants
INTERVENTIONAL
Beijing, China
Started: May 25, 2023
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
NCT06676631RECRUITINGPHASE1
18 participants
INTERVENTIONAL
Guangzhou, China
Started: Feb 19, 2025
Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis
NCT05207358RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Bucharest, Romania
Started: Mar 2, 2022
Completed Clinical Trials
8 completed trials for Rituximab in Lupus
Anti-CD20 in Systemic Lupus Erythematosus
NCT00036491COMPLETEDPHASE1, PHASE2
24 participants
INTERVENTIONAL
Denver, United States +2 more
Started: Jan 1, 2001
Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
NCT00556192COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Hong Kong, China
Started: Jun 1, 2006
Rituximab and Belimumab for Lupus Nephritis
NCT02260934COMPLETEDPHASE2
43 participants
INTERVENTIONAL
Birmingham, United States +14 more
Started: Jul 9, 2015
Synergetic B-cell Immodulation in SLE
NCT02284984COMPLETEDPHASE2
16 participants
INTERVENTIONAL
Leiden, Netherlands
Started: Mar 1, 2014
Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis
NCT00293072COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Cambridge, United Kingdom
Started: Mar 1, 2002
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
NCT00137969COMPLETEDPHASE2, PHASE3
262 participants
INTERVENTIONAL
Birmingham, United States +64 more
Started: May 10, 2005
A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
NCT00282347COMPLETEDPHASE3
144 participants
INTERVENTIONAL
Started: Jan 1, 2006
A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE
NCT03312907COMPLETEDPHASE3
292 participants
INTERVENTIONAL
Birmingham, United States +78 more
Started: Mar 1, 2018
Showing 20 of 36 total trials